MedTrace Logo

An Interaction Study With Digoxin and AZD1305

NCT00712465 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2010-12-03

No results posted yet for this study

Summary

The primary purpose of this study is to learn more about how digoxin is handled by the body, i.e. absorption, distribution, metabolism and excretion, when administered alone and in combination with AZD1305. Secondary purposes are to learn more about how AZD1305 is handled by the body when administered alone and in combination with digoxin and to learn more about how AZD1305 and digoxin administered alone and in combination affect the body.

Conditions

Interventions

DRUG

AZD1305

Extended Release tablet, repeated administration

DRUG

Digoxin

Tablet, repeated administration

Sponsors & Collaborators

Principal Investigators

  • Helen Lunde, MD · AstraZeneca R&D, Mölndal, Sweden

  • Marianne Hartford, MD, PhD · AstraZeneca, Clinical Pharmacology Unit, Sahlgrenska University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00712465 on ClinicalTrials.gov